July 18, 2024 – Talk Bio

PhRMA Intensifies Pricing Criticism, Targets Shared Ownership of Insurers and PBMs in New Ad

9 months ago talkbio0Tagged Insurance Carriers, Ownership, PBMs, PhRMA, Pricing

PhRMA, pricing attack, shared ownership, insurers, PBMs, new ad

FDA Discourages Accelerated Approval for Agenus’ Colorectal Cancer Combination, Prompting Partnership Search

9 months ago talkbio0Tagged Accelerated, Agenus, Approved, balstilimab, Botensilimab, Colorectal Carcinoma, Combined, Immunotherapy, Partnership, Phase 3 Clinical Trials, United States Food and Drug Administration

Agenus, FDA, Accelerated Approval, Colorectal Cancer, Botensilimab, Balstilimab, Immunotherapy Combination, Phase III Trial, Partnership

The Best Practice Organization: Key to Success in Today’s Biopharma Industry

9 months ago talkbio0Tagged Anthropological Culture, Best Practice Organization, Biopharma Industry, Business Development, commercial field teams, Generative AI, Leadership, Medical Affairs, Practice Experience, Strategic Workforce Planning, Success Factors, Talent Strategy

Biopharma Industry, Best Practice Organization, Success Factors, Operational Excellence, Business Development Strategy, Talent Strategy, Medical Affairs, Commercial Field Teams, Generative AI, Integrated Teams, Strategic Workforce Planning, Leadership, Culture, Team Dynamics, Talent Experience

Johnson & Johnson Raises 2024 Guidance Following Acquisition of Shockwave Medical

9 months ago talkbio0Tagged 2024, Acquisition (action), Advice, billion-dollar, Johnson and Johnson, Shockwave Medical

Johnson & Johnson, Shockwave Medical, 2024 Guidance, Acquisition, Billion-Dollar Potential

Orexo’s Opioid Overdose Nasal Spray Fails FDA Review for Second Time

9 months ago talkbio0Tagged Drug Overdose, Homo sapiens, naloxone, Nasal Spray, Opioids, Orexo, OX124, Technical Data, Techniques, United States Food and Drug Administration

Orexo, OX124, FDA, Nasal Spray, Opioid Overdose, Naloxone, Human Factors Study, Technical Data

Biopharma Layoff Tracker 2024: Thousands of Jobs Cut Across Industry Giants

9 months ago talkbio0Tagged 2024, Biopharma layoffs, Financial cost, Gigantism, Industry, restructuring

Biopharma Layoffs, 2024, Industry Giants, Job Cuts, Restructuring, Cost Savings

Bayer’s NUBEQA Shows Promise in Prostate Cancer Treatment, Expanding Indications

9 months ago talkbio0Tagged ARAMIS, ARASENS, Bayer, Clinical Trials, Corporation, darolutamide, Hormone Responsive, Malignant neoplasm of prostate, Metastatic to, non-metastatic castration-resistant prostate cancer, Nubeqa, Orion

NUBEQA, darolutamide, prostate cancer, metastatic hormone-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, ARASENS trial, ARAMIS trial, Bayer, Orion Corporation